Vestar
Executive Summary
Phase I clinicals of the company's targeted liposomal daunorubicin to begin soon. The trial will involve patients with metastatic tumors. Vestar intends the Phase II portion of the study to focus on treating tumors of various types, particularly Kaposi's sarcoma. Vestar in collaboration with LyphoMed has another liposomal cancer drug in clinicals. A Phase II trial of liposomal doxorubicin is ongoing at Georgetown University. Under the 50/50 R&D venture, Vestar retains manufacturing rights and LyphoMed handles marketing and sales.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.